EpiCept Corporation’s Senior Director of Lead Discovery, Dr. John Drewe, will present at the IBC at the Hotel Del Coronado in San Diego, CA on October 17, 2007.

During this presentation, Dr. Drewe will describe the advances into pre-clinical testing of drug discovery efforts targeting the Myc oncogene pathway utilizing EpiCept’s Anti-cancer Screening Apoptosis Platform.

EpiCept’s apoptosis screening technology can identify new cancer drug candidates and molecular targets that have the ability to reduce cancer cells through the use of genetics and live cell high-throughput caspase-3 screening technology.

EpiCept has identified several compounds that can induce apoptosis in cancer cells. Several compounds from within these families have progressed to lead drug candidate status with proven pre-clinical efficacies in tumor models and identified molecular targets.

Let us hear your thoughts below: